Please provide your email address to receive an email when new articles are posted on . One in six participants in phase 2 cancer trials received a therapy that gained FDA approval. The results ...
Rentosertib, an AI-discovered TNIK inhibitor, showed safety and tolerability in a phase 2a trial for idiopathic pulmonary fibrosis. The trial involved 71 patients, with similar adverse event rates ...
Veradermics, Incorporated, a dermatologist-founded, late clinical-stage biopharmaceutical company developing potentially first-in-class therapeutics for common dermatologic conditions, today announced ...
NEW YORK and MELBOURNE, Australia, April 03, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing new ...
Cerevance’s attempt to unlock the first-line Parkinson's disease market has hit a snag, with solengepras performing no better than placebo in phase 2 when given to people with early, untreated ...
Phase 2 trial launched for verekitug in COPD, expanding treatment indications for severe respiratory conditions. Top data expected in 2026. Upstream Bio, Inc. has initiated a global Phase 2 clinical ...
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare ...
MEDISEP Phase II launches January 1, 2026, with increased premiums and coverage, facing criticism from employees over hospital access.
ORLANDO, Fla. — A second phase 2 trial with the tyrosine kinase 2 (TYK2) inhibitor deucravacitinib has met the primary efficacy endpoints for the treatment of the skin manifestations of cutaneous ...
Maridebart cafraglutide (Amgen), also known as MariTide or AMG133, helps patients with obesity—whether or not they also have diabetes—lose substantial amounts of body weight, according to newly ...
Maridebart cafraglutide showed up to 19.9% weight loss in obesity and 17% in obesity-diabetes patients in a phase 2 trial. The drug's 21-day half-life, combining GLP-1 receptor agonism and GIP ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback